Spyre Therapeutics, Inc. SYRE Income Tax
Income Tax at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s income tax?
- Spyre Therapeutics, Inc. (SYRE) reported income tax of $0 in Q1 2026.
- How has Spyre Therapeutics, Inc.'s income tax changed year-over-year?
- Spyre Therapeutics, Inc.'s income tax increased by 100.0% year-over-year, from -$15K to $0.
- What is the long-term trend for Spyre Therapeutics, Inc.'s income tax?
- Over 3 years (2021 to 2025), Spyre Therapeutics, Inc.'s income tax has grown at a -52.6% compound annual growth rate (CAGR), from $141K to -$15K.
- What does income tax mean?
- The total amount of tax expense or benefit recognized by the company for the period.
- How do you interpret income tax?
- An increase in tax expense typically reflects higher taxable profits, while a tax benefit indicates the utilization of tax credits or the recognition of deferred tax assets during periods of net loss.
- How does income tax compare across companies?
- Biotech firms in early clinical stages often report minimal or negative tax expenses due to recurring operating losses and the accumulation of net operating loss carryforwards.